• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    11/14/23 2:05:46 PM ET
    $ABSI
    $ACIC
    $ADPT
    $AIRE
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Property-Casualty Insurers
    Finance
    Get the next $ABSI alert in real time by email

    Shares of Beyond Air, Inc. (NASDAQ:XAIR) dipped during Tuesday’s session following weak quarterly results.

    Beyond Air posted a quarterly loss of 51 cents per share, versus market estimates of 51 cents per share. The company’s quarterly sales came in $239,000, versus expectations of $480,000.

    Beyond Air shares fell 37.3% to $1.2701 on Tuesday.

    Here are other stocks moving in today's session.

    Gainers

    • BioCardia, Inc. (NASDAQ:BCDA) shares jumped 235.8% to $1.34 after the company announced the FDA approval of its Phase 3 clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.
    • reAlpha Tech Corp. (NASDAQ:AIRE) shares surged 67.4% to $9.86 after jumping around 34% on Monday.
    • Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) shares rose 47.5% to $3.16 after the company announced process to explore strategic alternatives.
    • SuperCom Ltd. (NASDAQ:SPCB) gained 38% to $0.5153 following third-quarter earnings.
    • INVO Bioscience, Inc. (NASDAQ:INVO) shares climbed 37.3% to $2.21 after the company posted a narrower loss for the third quarter.
    • Talis Biomedical Corporation (NASDAQ:TLIS) gained 33.4% to $7.19 as the company announced exploration of strategic alternatives and cost reduction plan to preserve cash.
    • PureCycle Technologies, Inc. (NASDAQ:PCT) gained 27.7% to $3.91.
    • Hyzon Motors Inc. (NASDAQ:HYZN) surged 24.3% to $0.9798 following third-quarter results.
    • American Coastal Insurance Corporation (NASDAQ:ACIC) gained 23.8% to $8.48 following quarterly results.
    • Cutera, Inc. (NASDAQ:CUTR) rose 20% to $2.10.
    • Farfetch Limited (NYSE:FTCH) gained 19.3% to $1.5750.
    • Portage Biotech Inc. (NASDAQ:PRTG) rose 19% to $1.44.
    • Sunnova Energy International Inc. (NYSE:NOVA) gained 18.5% to $10.10.
    • RedHill Biopharma Ltd. (NASDAQ:RDHL) climbed 18.3% to $0.3666.
    • Janux Therapeutics, Inc. (NASDAQ:JANX) rose 15.8% to $8.21.
    • Sally Beauty Holdings, Inc. (NYSE:SBH) climbed 15.5% to $9.39 following fourth-quarter earnings.
    • Adaptive Biotechnologies Corporation (NASDAQ:ADPT) gained 15.1% to $3.9750. Piper Sandler maintained Adaptive Biotechnologies with an Overweight and lowered the price target from $13 to $6.
    • Ameresco, Inc. (NASDAQ:AMRC) climbed 15.1% to $25.92.
    • Lyell Immunopharma, Inc. (NASDAQ:LYEL) gained 14.8% to $1.78.
    • Anywhere Real Estate Inc. (NASDAQ:HOUS) gained 14.3% to $5.05.
    • Pacific Biosciences of California, Inc. (NASDAQ:PACB) rose 14.1% to $7.34.
    • PodcastOne, Inc. (NASDAQ:PODC) gained 14% to $2.68.
    • SL Green Realty Corp. (NYSE:SLG) climbed 14% to $33.75.
    • Plug Power Inc. (NASDAQ:PLUG) rose 13.8% to $3.95.
    • Uniti Group Inc. (NASDAQ:UNIT) climbed 13.6% to $5.17.
    • Sunrun Inc. (NASDAQ:RUN) gained 13.5% to $10.48.
    • Digital Health Acquisition Corp. (NASDAQ:DHAC) climbed 12.2% to $13.80.
    • The E.W. Scripps Company (NASDAQ:SSP) jumped 11% to $7.35.
    • Evoke Pharma, Inc. (NASDAQ:EVOK) gained 9.6% to $1.4034.
    • Zillow Group, Inc. (NASDAQ:Z) gained 9.2% to $38.98. PHH Mortgage announced new subservicing agreement with Zillow Home Loans.
    • Snap Inc. (NYSE:SNAP) rose 9% to $12.32 following reports suggesting Amazon has reached a deal to run shopping ads on the app.
    • Absci Corporation (NASDAQ:ABSI) rose 8.8% to $1.36. Almirall and Absci disclosed AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases.
    • PaxMedica, Inc. (NASDAQ:PXMD) gained 7% to $1.8293. The company recently announced research findings in the Annals of General Psychiatry regarding a study on low-dose suramin intravenous infusions as a potential treatment for Autism Spectrum Disorder.

    Losers

    • Li-Cycle Holdings Corp. (NYSE:LICY) shares tumbled 61.5% to $0.5633. The company reported third-quarter financial results.
    • The Beauty Health Company (NASDAQ:SKIN) shares fell 61% to $1.52 after the company reported weaker-than-expected financial results for its third quarter and revised its net sales outlook. Also, the company suspended its long-term full-year 2025 forecast.
    • Kubient, Inc. (NASDAQ:KBNT) were down 54% to $0.1001. Kubient announced voluntary delisting from Nasdaq Capital Market.
    • Applied UV, Inc. (NASDAQ:AUVI) was down, falling 44% to $0.1504. Applied UV announced pricing of $6.4 million upsized underwritten public offering of 42,666,666 units at $0.15 per unit.
    • Harrow, Inc. (NASDAQ:HROW) shares fell 37% to $8.10 as the company reported downbeat third-quarter financial results and lowered its revenue guidance.
    • Gamida Cell Ltd. (NASDAQ:GMDA) fell 34.2% to $0.39 as the company reported third-quarter financial results.
    • Renalytix Plc (NASDAQ:RNLX) fell 28.3% to $0.6088 following first-quarter results.
    • BioXcel Therapeutics, Inc. (NASDAQ:BTAI) dipped 23.1% to $4.2399 following weak quarterly results.
    • Sea Limited (NYSE:SE) fell 21.7% to $36.00 after the company reported quarterly financial results.
    • Fisker Inc. (NYSE:FSR) shares fell 21.7% to $3.2165 following third-quarter results.
    • Salem Media Group, Inc. (NASDAQ:SALM) fell 21.1% to $0.60 following third-quarter results.
    • Asure Software, Inc. (NASDAQ:ASUR) fell 21.1% to $6.76 following third-quarter results.
    • Lufax Holding Ltd (NYSE:LU) declined 18.8% to $0.8277 following third-quarter results.
    • NET Power Inc. (NYSE:NPWR) fell 17.2% to $11.03 after the company reported worse-than-expected third-quarter EPS results.
    • Tenax Therapeutics, Inc. (NASDAQ:TENX) fell 16.2% to $0.5199. Tenax Therapeutics shares jumped 297% on Monday morning after the company received FDA clearance of the IND for TNX-103, an oral levosimendan, to treat pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
    • TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) fell 13.1% to $0.1860 after declining around 7% on Monday. TRACON Pharma recently posted a profit for the third quarter.
    • Hut 8 Mining Corp. (NASDAQ:HUT) fell 13% to $1.7699 following third-quarter results.
    • Beneficient (NASDAQ:BENF) fell 13% to $0.5736 following second-quarter results.
    • MicroStrategy Incorporated (NASDAQ:MSTR) declined 8.3% to $462.26.
    • Peraso Inc. (NASDAQ:PRSO) shares fell 8% to $0.22 after the company announced third-quarter results.
    • Akili, Inc. (NASDAQ:AKLI) shares fell 7.1% to $0.4105. The company recently posted a narrower-than-expected quarterly loss.
    • Runway Growth Finance Corp. (NASDAQ:RWAY) fell 7.1% to $12.29. Runway Growth Finance priced secondary offering of 3.75 million common shares by selling stockholders at $12.56 per share.

    Now Read This: Nasdaq Surges 2%; US Inflation Rate Slows In October

    Get the next $ABSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI
    $ACIC
    $ADPT
    $AIRE

    CompanyDatePrice TargetRatingAnalyst
    Strategy Inc
    $MSTR
    3/10/2026$175.00Buy
    B. Riley Securities
    Lyell Immunopharma Inc.
    $LYEL
    3/9/2026$34.00Mkt Outperform
    Citizens
    Pacific Biosciences of California Inc.
    $PACB
    3/6/2026$1.50Equal Weight → Underweight
    Barclays
    Snap Inc.
    $SNAP
    2/10/2026$7.30Neutral → Buy
    Arete
    Snap Inc.
    $SNAP
    2/6/2026$5.50Sell → Hold
    Stifel
    Snap Inc.
    $SNAP
    2/5/2026$10.00Neutral → Buy
    BofA Securities
    Hut 8 Corp.
    $HUT
    2/2/2026$80.00Buy
    H.C. Wainwright
    Strategy Inc
    $MSTR
    1/27/2026$213.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ABSI
    $ACIC
    $ADPT
    $AIRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Strategy Inc with a new price target

    B. Riley Securities initiated coverage of Strategy Inc with a rating of Buy and set a new price target of $175.00

    3/10/26 8:42:16 AM ET
    $MSTR
    Computer Software: Prepackaged Software
    Technology

    Citizens initiated coverage on Lyell Immunopharma with a new price target

    Citizens initiated coverage of Lyell Immunopharma with a rating of Mkt Outperform and set a new price target of $34.00

    3/9/26 9:07:38 AM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacific Biosciences downgraded by Barclays with a new price target

    Barclays downgraded Pacific Biosciences from Equal Weight to Underweight and set a new price target of $1.50

    3/6/26 8:26:02 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABSI
    $ACIC
    $ADPT
    $AIRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Arch Venture Partners Ix, Llc bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/9/26 4:36:20 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Fund Xiii, L.P. bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/9/26 4:34:54 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Granado Corina S. bought $266,725 worth of Class A Common Shares (60,266 units at $4.43), increasing direct ownership by 9% to 720,517 units (SEC Form 4)

    4 - E.W. SCRIPPS Co (0000832428) (Issuer)

    3/6/26 5:00:35 PM ET
    $SSP
    Broadcasting
    Industrials

    $ABSI
    $ACIC
    $ADPT
    $AIRE
    SEC Filings

    View All

    Plug Power Inc. filed SEC Form 8-K: Leadership Update

    8-K - PLUG POWER INC (0001093691) (Filer)

    3/10/26 4:01:01 PM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    SEC Form 144 filed by Hut 8 Corp.

    144 - Hut 8 Corp. (0001964789) (Subject)

    3/10/26 3:28:22 PM ET
    $HUT
    Finance: Consumer Services
    Finance

    Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    3/10/26 8:26:19 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ACIC
    $ADPT
    $AIRE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    March 22, 2024 - FDA Roundup: March 22, 2024

    For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

    3/22/24 5:02:42 PM ET
    $SNAP
    $SRAX
    Computer Software: Programming Data Processing
    Technology
    Advertising
    Consumer Discretionary

    November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

    For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

    11/9/23 2:30:20 PM ET
    $SRAX
    $SNAP
    Advertising
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    $ABSI
    $ACIC
    $ADPT
    $AIRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

    NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale in a registered direct offering of 4,500,785 shares (the "Shares") of common stock, par value $0.001 per share ("Common Stock") (or common stock equivalents in lieu thereof), and accompanying warrants (the "Accompanying Warrants") to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per comm

    3/10/26 2:36:00 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    SuperCom Secures 4th New Electronic Monitoring Contract in Kentucky, Expansion Momentum Continues

    Kentucky momentum continues as SuperCom advances its broader U.S. growth strategyDirect agency selection and incumbent displacement validate technology, execution, and market positioningNEW YORK, March 10, 2026 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, today announced that it has secured a new direct agency electronic monitoring (EM) contract with a county government agency in Kentucky. The agreement marks SuperCom's 4th new contract in the state since mid-2024, building on the Company's growing momentum across neighboring jurisdictions. SuperCom will deploy it's PureSecurity GPS electronic monitoring

    3/10/26 9:24:00 AM ET
    $SPCB
    Semiconductors
    Technology

    $ABSI
    $ACIC
    $ADPT
    $AIRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by NET Power Inc.

    4 - NET Power Inc. (0001845437) (Issuer)

    3/10/26 6:01:11 PM ET
    $NPWR
    Industrial Machinery/Components
    Energy

    SEC Form 4 filed by NET Power Inc.

    4 - NET Power Inc. (0001845437) (Issuer)

    3/10/26 6:02:02 PM ET
    $NPWR
    Industrial Machinery/Components
    Energy

    SEC Form 4 filed by E.W. Scripps Company

    4 - E.W. SCRIPPS Co (0000832428) (Issuer)

    3/10/26 5:00:14 PM ET
    $SSP
    Broadcasting
    Industrials

    $ABSI
    $ACIC
    $ADPT
    $AIRE
    Leadership Updates

    Live Leadership Updates

    View All

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

    Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somarat

    3/3/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Plug Power Welcomes Jose Luis Crespo as Chief Executive Officer

    SLINGERLANDS, N.Y., March 03, 2026 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ:PLUG), a global leader in comprehensive hydrogen solutions, welcomes Jose Luis Crespo as Chief Executive Officer, marking the start of the Company's next phase of disciplined growth and focused execution. Crespo assumed the role on March 2, 2026. Crespo brings more than 12 years of leadership experience at Plug, most recently serving as President and Chief Revenue Officer, where he drove growth through cost discipline, margin expansion, and capital efficiency. He led Plug's commercial organization during a period of significant scale, helping grow revenue from approximately $27 million in 2013 to more than $700

    3/3/26 7:00:00 AM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    $ABSI
    $ACIC
    $ADPT
    $AIRE
    Financials

    Live finance-specific insights

    View All

    Net Power Reports Fourth Quarter and Year End 2025 Results and Provides Business Update

    Net Power Inc. (NYSE:NPWR) ("Net Power" or the "Company") today announced its financial and operational results for the fourth quarter and full year ended December 31, 2025. "We continue to see high demand for clean baseload power into next decade, and we are excited to be making tangible progress towards the first operational natural gas power plus CCS project in the United States alongside strategic partners in Entropy and Oxy," said Danny Rice, Chief Executive Officer of Net Power. "For now, the team continues to focus on obtaining a final investment decision by the second half of 2026, preserving our targeted commercial operations date in early 2029 for our first deployment. We look f

    3/9/26 4:15:00 PM ET
    $NPWR
    Industrial Machinery/Components
    Energy

    PodcastOne (Nasdaq: PODC) Acquires Four Podcasts In Multi-Year Deals Bringing Network Total to 208; 6 Podcasts Added to Date in 2026

    LOS ANGELES, March 05, 2026 (GLOBE NEWSWIRE) -- PodcastOne (NASDAQ:PODC), a leading publisher and podcast sales network, announced today that it has acquired multi-year exclusive sales and distribution rights to podcasts No Filter with host Zack Peter, Wellness Cafe with host Trinity Tondeleir, Daddy Issues with Violet Benson and Michelle Collins' eponymous podcast, Michelle Collins. "PodcastOne is dedicated to our quest to bring to our network the best, most diversified and cross genre podcasts. With the additions of No Filter, Wellness Cafe, Michelle Collins and being able to welcome back Daddy Issues, we've aligned with podcasts that pair well with our existing shows while continuing t

    3/5/26 8:00:00 AM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    Sea Limited Reports Fourth Quarter and Full Year 2025 Results

    Sea Limited (NYSE:SE) ("Sea" or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2025. In the fourth quarter of 2025, Sea's GAAP revenue was US$6.9 billion, up 38.4% year-on-year. The Company also achieved gross profit of US$3.0 billion, up 36.0% year-on-year, and net income of US$410.9 million, up 72.9% year-on-year. Adjusted EBITDA1 increased by 33.2% year-on-year to reach US$787.1 million. For the full year of 2025, Sea's GAAP revenue was US$22.9 billion, up 36.4% year-on-year, with gross profit growing 42.2% year-on-year to US$10.2 billion. Net income reached US$1.6 billion, as compared to net income of US$447.8 million for

    3/3/26 6:30:00 AM ET
    $SE
    Other Consumer Services
    Consumer Discretionary

    $ABSI
    $ACIC
    $ADPT
    $AIRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Li-Cycle Holdings Corp.

    SC 13D/A - Li-Cycle Holdings Corp. (0001828811) (Subject)

    12/9/24 6:03:27 PM ET
    $LICY
    Environmental Services
    Industrials

    Amendment: SEC Form SC 13D/A filed by Lufax Holding Ltd

    SC 13D/A - Lufax Holding Ltd (0001816007) (Subject)

    12/9/24 6:12:27 AM ET
    $LU
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care